SCHEMBL4155853

SCHEMBL4155853

Nc1ccc(Cc2ccccc2)o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.46
CALM1 P0DP23 1/20 0.46
LTB4R Q15722 2/20 0.40
ALDH1A1 P00352 1/20 0.37
LOXL2 Q9Y4K0 1/20 0.37
IDH1 O75874 1/20 0.37
MAOA P21397 2/20 0.37
MAOB P27338 2/20 0.37
HTR2A P28223 1/20 0.36
AOC3 Q16853 1/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20163176 0.84 CALM1 (0.58) CTSLCALM1IDH1NPC1HPGD
SCHEMBL31037931 0.81 HTT (0.35) ALDH1A1
SCHEMBL31037930 0.81 HTT (0.35) ALDH1A1
SCHEMBL1680764 0.78 CYP2A6 (0.53) CTSLCALM1LTB4RLOXL2IDH1
Hydrochloric Acid SCHEMBL1169925 0.77 CYP2A6 (0.52) CTSLCALM1LOXL2IDH1MAOB
SCHEMBL10910046 0.74 CALM1 (0.46) CTSLCALM1ALDH1A1IDH1NPC1
SCHEMBL3180066 0.74 CHRM2 (0.47) CTSLCALM1ALDH1A1NPC1RAB9A
SCHEMBL18294977 0.74 CALM1 (0.46) CTSLCALM1IDH1NPC1HPGD
SCHEMBL9338807 0.74 TDP1 (0.50) CTSLCALM1ALDH1A1IDH1NPC1
SCHEMBL27968343 0.74 TP53 (0.48) CTSLCALM1ALDH1A1IDH1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD CTSL 93/4885CALM1 1782/4885LTB4R 2696/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 CTSL 86/4885CALM1 3866/4885LTB4R 2345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.